The promise of personalized medicine will be fully realized when a person's state of health can be understood at the moment of medical examination. Genetic and genomic technologies, although powerful, are ultimately only predictors of potential disease. Genes lack the immediacy needed for "just-in-time" diagnosis and treatment selection. Truly successful medicine needs to detect disease at its earliest possible stages in real time, which requires accurately measuring the combination of proteins that make up the body.
SomaLogic, Inc., is a privately held protein biomarker discovery and clinical diagnostics company based in Boulder, Colorado. Our mission is to leverage our proprietary Slow Off-rate Modified Aptamer (“SOMAmer”) technology to:
• Develop and commercialize breakthrough clinical diagnostic products that will transform healthcare;
• Facilitate biomarker discovery and validation for our biopharmaceutical and other partners.